A patient is anxious about what his therapist truly thinks about him. Does the patient have a right to review the therapist’s ...

Commercial Cell and Gene Therapy Revenue -- $9.1 million, up 26% year over year, reflecting growth in therapies supported.

It's certainly a sentiment I've heard more than a few times- that it's just something that's become accepted when it doesn't ...

United Therapeutics Corporation (NASDAQ: UTHR) Q1 2026 Earnings Call Transcript May 6, 2026 United Therapeutics Corporation ...

Speech therapy documentation isn’t just paperwork—it’s the foundation for effective treatment, legal compliance, and professional credibility. From structured note formats to HIPAA-compliant digital ...

In the ever evolving landscape of autism care, expectations are shifting. Families are looking for care that reflects the ...

Jazz announced U.S. FDA acceptance with Priority Review of Supplemental Biologics License Application (sBLA) for zanidatamab in first-line HER2-positive unresectable locally advanced or metastatic ...

To find out if a woman has cancer doctors do a few different tests. They do imaging tests like ultrasounds or CT scans to ...

Sleep Apnea Solution author Dylan Petkus, MD, has developed a non-device, behavior-based alternative approach to sleep apnea.

Daraxonrasib demonstrated unprecedented survival benefit in Phase 3 RASolute 302 trial in previously treated metastatic pancreatic cancer; ...

From data quality and AI readiness to the realities of clinical translation, industry leaders share where precision still ...

Q1 2026 earnings call recap: revenue up 16%, FY guidance raised to $192–$196M, 766 trials supported, EBITDA nearing breakeven—read now.